Eugene Ichinose, MD
Interventional Cardiology · Tulsa, OKNPI 1952378978
Payments from drug & device makers
Across 587 payments — averaging $247.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$109K
- Pfizer$14K
- Penumbra, Inc.$11K
- E.r. Squibb & Sons, L.L.C.$2K
- Abiomed$2K
- Angiodynamics, Inc.$1K
- plus $5K from 31 others
What the payments were for
- Consulting fees$6,37513%
- Speaking & faculty fees$17,70036%
- Travel & lodging$6,56113%
- Food & beverage$18,49938%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 198 | $109,382 |
| Pfizer | 96 | $13,966 |
| Penumbra, Inc. | 43 | $10,669 |
| E.r. Squibb & Sons, L.L.C. | 28 | $2,484 |
| Abiomed | 36 | $2,442 |
| Angiodynamics, Inc. | 17 | $1,446 |
| Bard Peripheral Vascular, Inc. | 16 | $846 |
| Medtronic | 14 | $582 |
| Imperative Care, Inc | 8 | $456 |
| Stryker | 16 | $371 |
| Abbott | 12 | $354 |
| Boehringer Ingelheim | 12 | $316 |
| Amgen | 13 | $248 |
| Merck | 13 | $223 |
| Philips North America LLC | 5 | $216 |
| Surmodics, Inc. | 3 | $202 |
| Novo Nordisk | 5 | $196 |
| Boston Scientific | 8 | $190 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $101 |
| Novartis | 4 | $95 |
| Bayer | 5 | $85 |
| Lexicon Pharmaceuticals, Inc. | 4 | $82 |
| Acist Medical Systems, Inc. | 1 | $67 |
| Heartflow, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $49 |
| Cardiva Medical, Inc. | 2 | $49 |
| Actelion Pharmaceuticals US, Inc. | 3 | $48 |
| AstraZeneca | 3 | $48 |
| Asahi Intecc USA, Inc. | 1 | $39 |
| Edwards Lifesciences | 2 | $38 |
| Silk Road Medical, Inc. | 1 | $29 |
| Livanova USA, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$15,843
- ELIQUIS$14,193
- Indigo System$8,701
- FLOWTRIEVER CATHETER, S$5,995
- Impella$1,405
- FlowTriever$1,019
- RUBY Coil$976
- ClotTriever$894
- Venclose Maven Catheter$439
- AlphaVac$402
- SYMPHONY CATHETER$304
- Sublime 014 Rx PTA Balloon Dilatation Catheter$143
- Sublime Radial Access 018 RX PTA Dilatation Catheter$143
- Sublime Radial Access Guide Sheath$143
- Pounce Thrombectomy$143
- Pounce Venous Thrombectomy System$143
- ClosureFast$137
- HawkOne$135
- VENOVO$134
- AMPLATZER Occluders$128
How this compares
$145,485 in reported general payments places this provider in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 315 | $282,085 |
| XareltoRivaroxaban | 88 | $84,303 |
| EntrestoSacubitril/Valsartan | 71 | $81,093 |
| JardianceEmpagliflozin | 65 | $58,258 |
| FarxigaDapagliflozin Propanediol | 66 | $48,086 |
| Repatha SureclickEvolocumab | 57 | $37,865 |
| BrilintaTicagrelor | 39 | $25,816 |
| VascepaIcosapent Ethyl | 48 | $21,215 |
| MounjaroTirzepatide | 21 | $19,242 |
| OzempicSemaglutide | 12 | $11,242 |
| Ranolazine ErRanolazine | 69 | $6,581 |
| Ezetimibe | 326 | $6,053 |
| Icosapent Ethyl | 17 | $5,138 |
| Atorvastatin Calcium | 428 | $3,414 |
| Metoprolol Succinate | 258 | $2,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13,966 | $282,085315 claims |
| Johnson & JohnsonXarelto | $49 | $84,30388 claims |
| NovartisEntresto | $95 | $81,09371 claims |
| AstraZenecaFarxiga, Brilinta | $48 | $73,902105 claims |
| Boehringer IngelheimJardiance | $316 | $58,25865 claims |
| Novo NordiskOzempic | $196 | $11,24212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$5.7M
- Wayne LeimbachTulsa$283K
- Stanley ZimmermanTulsa$102K
- Tucker HarrisonTulsa$97K
- Matthew ComstockTulsa$69K
- Tom HuTulsa$57K
- Poorya FazelTulsa$29K
- Stewart KatzTulsa$22K
- Andrew KurklinskyTulsa$16K
- Rajesh ChandwaneyTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.